Possibilities of using ambazone (Faringosept) in infectious and inflammatory diseases of oropharynx. A review

Cover Page

Cite item

Full Text

Abstract

The incidence of acute respiratory infections has remained the same for decades. About 70–80 thousand cases per 100 thousand children are registered annually in the Russian Federation, which is 3.3 times higher than in adults. For the last reporting year, 2022, the incidence of acute respiratory viral infections (ARVI) was almost twice the long-term average. Influenza is a highly contagious severe respiratory infection, the incidence of which peaked in December 2022. At the beginning of the epidemic season, influenza A(H1N1) pdm09 viruses prevailed, and then they were joined by influenza B viruses with more severe disease than in previous years. Compared to 2021, the number of reported cases is 4 times higher, twice the long-term average. Most respiratory viral infections, having their specific features, involve the nasal mucosa and oropharynx and manifest with sore throat, rhinitis, cough, and fever. The study of the oral and pharyngeal microbiota by 16S rRNA gene sequencing showed that in patients with ARVI, there is a significant decrease in the α-diversity of bacteria and the loss of a healthy basic microbiota, in particular anaerobes and Prevotella spp. At the same time, eight respiratory pathogens were identified, including Staphylococcus aureus, Haemophilus influenzae, Streptococcus pneumoniae, Moraxella catarrhalis, lichen pigmentosa and Corynebacterium propinquum/pseudodiphtheriticum, which commonly cause bacterial complications, especially in children with frequent respiratory infections. The article addresses the treatment of ARVI and tonsillopharyngitis in children following clinical guidelines and the prospects of using topical agents for inflammation of the oropharynx in children.

Full Text

Restricted Access

About the authors

Irina N. Zakharova

Russian Medical Academy of Continuous Professional Education

Author for correspondence.
Email: zakharova-rmapo@yandex.ru
ORCID iD: 0000-0003-4200-4598

Sci. (Med.), Prof., Russian Medical Academy of Continuous Professional Education

Russian Federation, Moscow

Irina V. Berezhnaya

Russian Medical Academy of Continuous Professional Education; Bashlyaeva Children’s City Clinical Hospital of the Moscow City Health Care Department

Email: berezhnaya-irina26@yandex.ru
ORCID iD: 0000-0002-2847-6268

Cand. Sci. (Med.)

Russian Federation, Moscow; Moscow

Irina S. Kuznetsova

Russian Medical Academy of Continuous Professional Education

Email: vanya771@mail.ru

Assistant

Russian Federation, Moscow

Natalia F. Dubovets

Bashlyaeva Children’s City Clinical Hospital of the Moscow City Health Care Department

Email: skorpionka_n@mail.ru

pediatrician, Department Head

Russian Federation, Moscow

References

  1. Баранов А.А., Альбицкий В.Ю., Иванова А.А., и др. Тенденции заболеваемости и состояние здоровья детского населения Российской Федерации. Российский педиатрический журнал. 2012;(6):4-9 [Baranov AA, Albitsky VYu, Ivanova AA, et al. Trends and the health status of the child population of the Russian Federation. The Russian Pediatric Journal. 2012;(6):4-9 (in Russian)].
  2. Ключников С.О., Зайцева О.В., Османов И.М., и др. Острые респираторные заболевания у детей. Пособие для врачей. М.: Медкнига, 2008. (Российский вестник перинатологии и педиатрии. Приложение 3.2008) [Kliuchnikov SO, Zaitseva OV, Osmanov IM, et al. Ostrye respiratornye zabolevaniia u detei. Posobie dlia vrachei. Moscow: Medkniga, 2008. (Rossiiskii vestnik perinatologii i pediatrii. Prilozhenie 3.2008) (in Russian)].
  3. Roux S, Hallam SJ, Woyke T, Sullivan MB. Viral dark matter and virus-host interactions resolved from publicly available microbial genomes. Elife. 2015;4:e08490. doi: 10.7554/eLife.08490
  4. Рябиченко Т.И., Скосырева Г.А., Обухова О.О., и др. Этиологическая структура острых респираторных вирусных инфекций у детей, госпитализированных в стационар в 2015–2018 гг. Инфекционные болезни: новости, мнения, обучение. 2021;10(2):47-53 [Ryabichenko TI, Skosyreva GA, Obukhova OO, et al. Etiological structure of acute respiratory viral infections in children hospitalized in 2015-2018. Infectious Diseases: News, Opinions, Training. 2021;10(2):47-53 (in Russian)]. doi: 10.33029/2305-3496-2021-10-2–47-53
  5. Correia W, Dorta-Guerra R, Sanches M, et al. Study of the Etiology of Acute Respiratory Infections in Children Under 5 Years at the Dr. Agostinho Neto Hospital, Praia, Santiago Island, Cabo Verde. Front Pediatr. 2021;9:716351. doi: 10.3389/fped.2021.716351
  6. О состоянии санитарно-эпидемиологического благополучия населения в Российской Федерации в 2022 году: Государственный доклад. М.: Федеральная служба по надзору в сфере защиты прав потребителей и благополучия человека, 2023 [O sostoianii sanitarno-epidemiologicheskogo blagopoluchiia naseleniia v Rossiiskoi Federatsii v 2022 godu: Gosudarstvennyi doklad. Moscow: Federal’naia sluzhba po nadzoru v sfere zashchity prav potrebitelei i blagopoluchiia cheloveka, 2023 (in Russian)].
  7. Савенкова М.С. Грипп и другие острые респираторные вирусные инфекции у детей. Аспекты противовирусной терапии. Consilium Medicum. Педиатрия (Прил.). 2016;3:73-8 [Savenkova MS. Influenza and other acute respiratory viral infections in children. Aspects of antiviral therapy. Consilium Medicum. Pediatrics (Suppl.). 2016;3:73-8 (in Russian)].
  8. Pavia AT. Viral infections of the lower respiratory tract: old viruses, new viruses, and the role of diagnosis. Clin Infect Dis. 2011;52(Suppl. 4):S284-9. doi: 10.1093/cid/cir043
  9. Мизерницкий Ю.Л., Мельникова И.М. Современная терапия острых респираторных вирусных инфекций и гриппа у детей: как противостоять полипрагмазии? Педиатрия (Прил. к журн. Consilium Medicum). 2018;3:69-73 [Mizernitskiy YuL, Melnikova IM. Modern therapy of acute respiratory viral infections and influenza in children: how to resist polypharmacy? Pediatrics (Suppl. Consilium Medicum). 2018;3:69-73 (in Russian)]. doi: 10.26442/2413-8460_2018.3.69-73
  10. Грипп у детей. Клинические рекомендации. ID: КР249. 2017 [Gripp u detei. Klinicheskie rekomendatsii. ID: KR249. 2017 (in Russian)].
  11. Радциг Е.Ю., Гуров А.В. Боль в горле. Перекрестье проблем и поиски решений. РМЖ. Мать и дитя. 2022;5(3):228-36 [Radtsig EYu, Gurov AV. Sore throat. Crossing problems and finding solutions. Russian Journal of Woman and Child Health. 2022;5(3):228-36 (in Russian)]. doi: 10.32364/2618-8430-2022-5–3-228-236
  12. Edouard S, Million M, Bachar D, et al. The nasopharyngeal microbiota in patients with viral respiratory tract infections is enriched in bacterial pathogens. Eur J Clin Microbiol Infect Dis. 2018;37(9):1725-33. doi: 10.1007/s10096-018-3305-8
  13. DeMuri GP, Gern JE, Eickhoff JC, et al. Dynamics of Bacterial Colonization With Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis During Symptomatic and Asymptomatic Viral Upper Respiratory Tract Infection. Clin Infect Dis. 2018;66(7):1045-53. doi: 10.1093/cid/cix941
  14. Pearce S, Bowen AC, Engel ME, et al. The incidence of sore throat and group A streptococcal pharyngitis in children at high risk of developing acute rheumatic fever: A systematic review and meta-analysis. PLoS One. 2020;15(11):e0242107. doi: 10.1371/journal.pone.0242107
  15. Острый тонзиллит и фарингит (Острый тонзиллофарингит). Клинические рекомендации. 2021 [Ostryi tonzillit i faringit (Ostryi tonzillofaringit). Klinicheskie rekomendatsii. 2021 (in Russian)].
  16. Claassen-Weitz S, Lim KYL, Mullally C, et al. The association between bacteria colonizing the upper respiratory tract and lower respiratory tract infection in young children: a systematic review and meta-analysis. Clin Microbiol Infect. 2021;27(9):1262-70. doi: 10.1016/j.cmi.2021.05.034
  17. Price R, MacLennan G, Glen J; SuDDICU Collaboration. Selective digestive or oropharyngeal decontamination and topical oropharyngeal chlorhexidine for prevention of death in general intensive care: systematic review and network meta-analysis. BMJ. 2014;348: g2197. doi: 10.1136/bmj.g2197
  18. Кладова О.В., Шамшева О.В. Клинически доказанная эффективность антисептического средства Фарингосепт® (Амбазон) за многолетний период его применения в медицинской практике. Практика педиатра. 2017;(4):66-70 [Kladova OV, Shamsheva OV. Klinicheski dokazannaia effektivnost’ antisepticheskogo sredstva Faringosept® (Ambazon) za mnogoletnii period ego primeneniia v meditsinskoi praktike. Praktika pediatra. 2017;(4):66-70 (in Russian)].
  19. Kacso I, Racz CP, Santa S, et al. Ambazone-lipoic acid salt: Structural and thermal characterization. Thermochimica Acta. 2012;550:13-8. doi: 10.1016/j.tca.2012.09.026
  20. Löber G, Hoffmann H. Ambazone as a membrane active antitumor drug. Biophys Chem. 1990;35(2-3):287-300. doi: 10.1016/0301-4622(90)80016-z
  21. Kiviranta UK, Maekitalo R. Tonsillitis acuta. Ubersicht ueber mikrobiologie und behandlung [Acute tonsillitis. Survey of microbiology and therapy]. Pract Oto-Rhino-Laryngol (Basel). 1964;26(Suppl. 1):1-30 [Article in German]. doi: 10.1159/000274619
  22. Fulga I, Neguţ M, Năşcuţiu AM, et al. Studiu privind sensibilitatea la ambazonă (Faringosept) a microbilor din izolate faringiene de la bolnavii cu infecţii acute ale căilor aeriene superioare [Microbial sensitivity to ambazone (Faringosept) in pharyngeal samples from patients with acute infections of the upper respiratory tract]. Bacteriol Virusol Parazitol Epidemiol. 2007;52(1-2):19-27 [Article in Romanian].
  23. Тимофеев А.А. Использование Фарингосепта для профилактики постэкстракционных воспалительных осложнений у больных с обострившимся хроническим периодонтитом. Стоматолог-практик. 2011;2:48-51 [Timofeev AA. Use Faringosept for the prevention of postextraction inflammatory complications in patients with aggravated chronic periodontitis. Dentist-practitioner. 2011;2:48-51 (in Russian)].

Supplementary files

Supplementary Files
Action
1. JATS XML
2. Fig. 1. Distribution of patients by age in three cities, Bucharest, Brașov and Târgu Mureș.

Download (98KB)
3. Fig. 2. The concentration of ambazone (Faringosept®) in the saliva of patients with nasopharyngeal infections and healthy subjects 30, 60, and 90 min after administration of the drug.

Download (117KB)

Copyright (c) 2024 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 74329 от 19.11.2018 г.